deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03018249

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus

Sponsor: NRG Oncology

Conditions FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Interventions Entinostat Hysterectomy Laboratory Biomarker Analysis Medroxyprogesterone Acetate
Updated 37 times since 2017 Last updated: Nov 15, 2021 Started: Oct 11, 2017 Primary completion: Apr 18, 2018 Completion: Mar 12, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma and is currently completed. NRG Oncology leads this study, which shows 37 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

37 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed EARLY_PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed EARLY_PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  4. Dec 2021 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

  5. Sep 2021 — Dec 2021 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 32 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Phase: PHASE2 → EARLY_PHASE1

  3. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  6. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  13. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  14. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  15. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  16. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  17. Mar 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  18. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  19. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  20. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  21. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  22. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  23. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  24. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  25. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  26. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE2

  27. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  28. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  29. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  30. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  31. May 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE2

  32. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Albany, United States , Albuquerque, United States , Anaconda, United States , Aurora, United States , Ballwin, United States , Baltimore, United States , Bardstown, United States , Beaver, United States , Belpre, United States and 146 more locations